Cooperative Agreement HT94252320048

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,170,041 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Hawaii (UH) to study the long-term safety and effectiveness of the Dengvaxia dengue vaccine in the Philippines. The key objectives are to determine the baseline dengue virus serostatus of Dengvaxia recipients, assess the long-term safety and effectiveness of the vaccine, and characterize the antibody and...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $294,583 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The funding supports the development of a novel, cost-effective multispecific therapeutic for dengue, a major global health concern. Mapp Biopharmaceutical is creating a tri-specific antibody fragment molecule designed to enhance therapeutic efficacy...

This Project Grant award of $1,211,704.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund comprehensive studies to elucidate the pathogenesis of severe dengue disease during primary infections. The research aims to determine differences in innate, antibody, and T-cell immune responses between severe primary and secondary dengue infections. The grant will leverage state-of-the-art tools and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding the development of a novel T cell-based vaccine to prevent dengue and Zika virus infections. The $781,718 award to Loyola University of Chicago will support the design and evaluation of a vaccine candidate that targets the Zika and dengue virus non-structural protein 3 (NS3) with the goal of inducing cytotoxic T lymphocyte responses without...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,754 to Nuravax, Inc. to evaluate the safety, tolerability, and immunogenicity of their adjuvanted preventive dual AB/tau vaccine, DUVAX, in healthy human volunteers. The award will fund a randomized, double-blind, placebo-controlled study to assess DUVAX's safety and ability to generate an immune response in participants aged 40-65. This research builds on preclinical studies...

The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $720,588 to the Regents of the University of Minnesota to develop safe and broadly protective vaccines against New World arenaviruses. The objective is to leverage a non-pathogenic arenavirus vector called RP18TRI to create live-attenuated vaccine candidates expressing antigens from the Junin and Machupo viruses. The...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,994,888 Cooperative Agreement under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Research Triangle Institute (RTI International) to establish and maintain the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (REVAMPP) Coordinating and Data Sharing Center (CDSC). The CDSC will coordinate the REVAMPP network, comprised of 6-8 research centers, to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop new malaria vaccine candidates based on the Pf Glutamic Acid Rich Protein (PFGARP) antigen. The $412,500 award will be used by the University of South Florida to evaluate immunodominant fragments of PFGARP for potential inclusion in a malaria vaccine, with a focus on improving efficacy against the deadly Plasmodium...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel high-throughput screening (HTS) assay platform that can directly monitor drug-induced changes in RNA levels of dengue and influenza viruses. The $300,000 award to Lucerna Inc., a minority-owned small disadvantaged business, will fund the creation of this HTS-compatible cell-based reporter system to...